Adverse event (AE) reporting is a critical safety monitoring activity in clinical trials that involves the identification, documentation, and timely reporting of any untoward medical occurrence in a trial subject. Under ICH E6 and ICH E2A, sponsors and investigators have specific obligations for detecting and reporting serious adverse events (SAEs) and other safety information.
What Is Adverse Event Reporting?
An adverse event is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational medicinal product, whether or not considered related to the product. A serious adverse event is any event that results in death, is life-threatening, requires hospitalization, causes persistent disability, or is a congenital anomaly. Investigators must assess the severity and causality of each AE and document findings in the subject’s source records and case report forms.
Regulatory Framework
AE reporting requirements are defined in ICH E6 Sections 4.11 and 5.17, ICH E2A for expedited reporting, and 21 CFR Part 312 in the United States. The EU Clinical Trials Regulation (536/2014) mandates electronic submission of SUSARs (Suspected Unexpected Serious Adverse Reactions) to the EudraVigilance database. Timelines for SAE reporting are strict: fatal or life-threatening events must be reported within 24 hours, and other SAEs within 15 days.
Key Requirements
Investigators must report all SAEs to the sponsor immediately, and the sponsor must conduct expedited reporting to regulatory authorities and ethics committees as required. Sponsors are responsible for safety signal detection and ongoing evaluation of the benefit-risk profile of the investigational product. A Data Safety Monitoring Board (DSMB) may be established for independent review of accumulating safety data.
Documentation
AE documentation must include a complete description of the event, onset and resolution dates, severity grade, causality assessment, and outcome. All AEs, including nonserious events, must be recorded in the subject’s source documents and captured in the clinical database. Safety reports, DSMB meeting minutes, and correspondence with regulators regarding safety findings are essential documents for the Trial Master File (TMF) .
Conclusion
Adverse event reporting is a cornerstone of subject safety protection in clinical trials. Compliance with regulatory timelines and accurate causality assessment are essential for ethical trial conduct. Sponsors and investigators must work together to ensure complete and timely reporting of all safety information.
